Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma

Massimo Terzolo, Silvia Bovio, Anna Pia, Pier Antonio Conton, Giuseppe Reimondo, Chiara Dall'Asta, Donatella Bemporad, Alberto Angeli, Giuseppe Opocher, Massimo Mannelli, Bruno Ambrosi, Franco Mantero

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objective: There is scant information on the morbidity associated with subclinical Cushing's syndrome in patients with a clinically inapparent adrenal adenoma. In the present study, we have determined the prevalence of alterations of the hypothalamic-pituitary-adrenal axis in such patients and examined whether any correlation between endocrine data and the clinical phenotype exists. Design and methods: A multi-institutional retrospective study was carried out on 210 patients (135 women and 75 men aged 19-81 years) with an adrenal adenoma detected serendipitously between 1996 and 2000 in four referral centers in Italy. Results: Hypertension was observed in 53.8%, obesity in 21.4% and hyperglycemia in 22.4% of patients. The 47 patients with midnight serum cortisol > 5.4 μg/dl, a value corresponding to the 97th centile of 100 controls, were older and displayed greater fasting glucose (120.4 ± 52.2 mg/dl vs 105.1 ± 39.2 mg/dl, P = 0.04) and systolic blood pressure (148.3 ± 14.6 mmHg vs 136.4 ± 16.2 mmHg, P = 0.0009) than the 113 patients with normal cortisol levels. The difference in systolic blood pressure remained statistically significant (P = 0.009) when age was used as a covariate. The percentage of hypertensive patients undergoing treatment was not different between the two groups (90.5 and 97.1%) but the percentage of patients with controlled hypertension was significantly lower among the hypercortisolemic patients (12.5 vs 32.4%, P = 0.04). Glycated haemoglobin (HbA1c) levels were higher in the hypercortisolemic diabetic patients (8.9 ± 1.1% vs 7.1 ± 1.3%, P = 0.005). Conclusions: Elevated midnight cortisol concentration is a reliable test to select a subgroup of patients with a clinically inapparent adrenal adenoma with an adverse cardiovascular risk profile.

Original languageEnglish
Pages (from-to)307-315
Number of pages9
JournalEuropean Journal of Endocrinology
Volume153
Issue number2
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Adenoma
Hydrocortisone
Serum
Blood Pressure
Hypertension
Cushing Syndrome
Glycosylated Hemoglobin A
Hyperglycemia
Italy
Fasting
Referral and Consultation
Retrospective Studies
Obesity
Morbidity
Phenotype
Glucose

ASJC Scopus subject areas

  • Endocrinology

Cite this

Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. / Terzolo, Massimo; Bovio, Silvia; Pia, Anna; Conton, Pier Antonio; Reimondo, Giuseppe; Dall'Asta, Chiara; Bemporad, Donatella; Angeli, Alberto; Opocher, Giuseppe; Mannelli, Massimo; Ambrosi, Bruno; Mantero, Franco.

In: European Journal of Endocrinology, Vol. 153, No. 2, 08.2005, p. 307-315.

Research output: Contribution to journalArticle

Terzolo, M, Bovio, S, Pia, A, Conton, PA, Reimondo, G, Dall'Asta, C, Bemporad, D, Angeli, A, Opocher, G, Mannelli, M, Ambrosi, B & Mantero, F 2005, 'Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma', European Journal of Endocrinology, vol. 153, no. 2, pp. 307-315. https://doi.org/10.1530/eje.1.01959
Terzolo, Massimo ; Bovio, Silvia ; Pia, Anna ; Conton, Pier Antonio ; Reimondo, Giuseppe ; Dall'Asta, Chiara ; Bemporad, Donatella ; Angeli, Alberto ; Opocher, Giuseppe ; Mannelli, Massimo ; Ambrosi, Bruno ; Mantero, Franco. / Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. In: European Journal of Endocrinology. 2005 ; Vol. 153, No. 2. pp. 307-315.
@article{a0bb6063ceea4cbc9a6bb85ef5501f52,
title = "Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma",
abstract = "Objective: There is scant information on the morbidity associated with subclinical Cushing's syndrome in patients with a clinically inapparent adrenal adenoma. In the present study, we have determined the prevalence of alterations of the hypothalamic-pituitary-adrenal axis in such patients and examined whether any correlation between endocrine data and the clinical phenotype exists. Design and methods: A multi-institutional retrospective study was carried out on 210 patients (135 women and 75 men aged 19-81 years) with an adrenal adenoma detected serendipitously between 1996 and 2000 in four referral centers in Italy. Results: Hypertension was observed in 53.8{\%}, obesity in 21.4{\%} and hyperglycemia in 22.4{\%} of patients. The 47 patients with midnight serum cortisol > 5.4 μg/dl, a value corresponding to the 97th centile of 100 controls, were older and displayed greater fasting glucose (120.4 ± 52.2 mg/dl vs 105.1 ± 39.2 mg/dl, P = 0.04) and systolic blood pressure (148.3 ± 14.6 mmHg vs 136.4 ± 16.2 mmHg, P = 0.0009) than the 113 patients with normal cortisol levels. The difference in systolic blood pressure remained statistically significant (P = 0.009) when age was used as a covariate. The percentage of hypertensive patients undergoing treatment was not different between the two groups (90.5 and 97.1{\%}) but the percentage of patients with controlled hypertension was significantly lower among the hypercortisolemic patients (12.5 vs 32.4{\%}, P = 0.04). Glycated haemoglobin (HbA1c) levels were higher in the hypercortisolemic diabetic patients (8.9 ± 1.1{\%} vs 7.1 ± 1.3{\%}, P = 0.005). Conclusions: Elevated midnight cortisol concentration is a reliable test to select a subgroup of patients with a clinically inapparent adrenal adenoma with an adverse cardiovascular risk profile.",
author = "Massimo Terzolo and Silvia Bovio and Anna Pia and Conton, {Pier Antonio} and Giuseppe Reimondo and Chiara Dall'Asta and Donatella Bemporad and Alberto Angeli and Giuseppe Opocher and Massimo Mannelli and Bruno Ambrosi and Franco Mantero",
year = "2005",
month = "8",
doi = "10.1530/eje.1.01959",
language = "English",
volume = "153",
pages = "307--315",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma

AU - Terzolo, Massimo

AU - Bovio, Silvia

AU - Pia, Anna

AU - Conton, Pier Antonio

AU - Reimondo, Giuseppe

AU - Dall'Asta, Chiara

AU - Bemporad, Donatella

AU - Angeli, Alberto

AU - Opocher, Giuseppe

AU - Mannelli, Massimo

AU - Ambrosi, Bruno

AU - Mantero, Franco

PY - 2005/8

Y1 - 2005/8

N2 - Objective: There is scant information on the morbidity associated with subclinical Cushing's syndrome in patients with a clinically inapparent adrenal adenoma. In the present study, we have determined the prevalence of alterations of the hypothalamic-pituitary-adrenal axis in such patients and examined whether any correlation between endocrine data and the clinical phenotype exists. Design and methods: A multi-institutional retrospective study was carried out on 210 patients (135 women and 75 men aged 19-81 years) with an adrenal adenoma detected serendipitously between 1996 and 2000 in four referral centers in Italy. Results: Hypertension was observed in 53.8%, obesity in 21.4% and hyperglycemia in 22.4% of patients. The 47 patients with midnight serum cortisol > 5.4 μg/dl, a value corresponding to the 97th centile of 100 controls, were older and displayed greater fasting glucose (120.4 ± 52.2 mg/dl vs 105.1 ± 39.2 mg/dl, P = 0.04) and systolic blood pressure (148.3 ± 14.6 mmHg vs 136.4 ± 16.2 mmHg, P = 0.0009) than the 113 patients with normal cortisol levels. The difference in systolic blood pressure remained statistically significant (P = 0.009) when age was used as a covariate. The percentage of hypertensive patients undergoing treatment was not different between the two groups (90.5 and 97.1%) but the percentage of patients with controlled hypertension was significantly lower among the hypercortisolemic patients (12.5 vs 32.4%, P = 0.04). Glycated haemoglobin (HbA1c) levels were higher in the hypercortisolemic diabetic patients (8.9 ± 1.1% vs 7.1 ± 1.3%, P = 0.005). Conclusions: Elevated midnight cortisol concentration is a reliable test to select a subgroup of patients with a clinically inapparent adrenal adenoma with an adverse cardiovascular risk profile.

AB - Objective: There is scant information on the morbidity associated with subclinical Cushing's syndrome in patients with a clinically inapparent adrenal adenoma. In the present study, we have determined the prevalence of alterations of the hypothalamic-pituitary-adrenal axis in such patients and examined whether any correlation between endocrine data and the clinical phenotype exists. Design and methods: A multi-institutional retrospective study was carried out on 210 patients (135 women and 75 men aged 19-81 years) with an adrenal adenoma detected serendipitously between 1996 and 2000 in four referral centers in Italy. Results: Hypertension was observed in 53.8%, obesity in 21.4% and hyperglycemia in 22.4% of patients. The 47 patients with midnight serum cortisol > 5.4 μg/dl, a value corresponding to the 97th centile of 100 controls, were older and displayed greater fasting glucose (120.4 ± 52.2 mg/dl vs 105.1 ± 39.2 mg/dl, P = 0.04) and systolic blood pressure (148.3 ± 14.6 mmHg vs 136.4 ± 16.2 mmHg, P = 0.0009) than the 113 patients with normal cortisol levels. The difference in systolic blood pressure remained statistically significant (P = 0.009) when age was used as a covariate. The percentage of hypertensive patients undergoing treatment was not different between the two groups (90.5 and 97.1%) but the percentage of patients with controlled hypertension was significantly lower among the hypercortisolemic patients (12.5 vs 32.4%, P = 0.04). Glycated haemoglobin (HbA1c) levels were higher in the hypercortisolemic diabetic patients (8.9 ± 1.1% vs 7.1 ± 1.3%, P = 0.005). Conclusions: Elevated midnight cortisol concentration is a reliable test to select a subgroup of patients with a clinically inapparent adrenal adenoma with an adverse cardiovascular risk profile.

UR - http://www.scopus.com/inward/record.url?scp=23844464511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844464511&partnerID=8YFLogxK

U2 - 10.1530/eje.1.01959

DO - 10.1530/eje.1.01959

M3 - Article

C2 - 16061838

AN - SCOPUS:23844464511

VL - 153

SP - 307

EP - 315

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -